argenxARGX
About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,639
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
135% more call options, than puts
Call options by funds: $236M | Put options by funds: $100M
22% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 144
2.43% less ownership
Funds ownership: 54.91% [Q1] → 52.48% (-2.43%) [Q2]
3% less funds holding
Funds holding: 442 [Q1] → 427 (-15) [Q2]
6% less funds holding in top 10
Funds holding in top 10: 18 [Q1] → 17 (-1) [Q2]
11% less capital invested
Capital invested by funds: $19.7B [Q1] → $17.7B (-$2.08B) [Q2]
13% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 60
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
RBC Capital Luca Issi | 25%upside $850 | Outperform Initiated | 25 Aug 2025 |
JP Morgan James Gordon | 23%upside $830 | Overweight Maintained | 4 Aug 2025 |
Guggenheim Yatin Suneja | 58%upside $1,070 | Buy Maintained | 1 Aug 2025 |
Morgan Stanley Matthew Harrison | 13%upside $766 | Overweight Maintained | 1 Aug 2025 |
HC Wainwright & Co. Douglas Tsao | 14%upside $774 | Buy Maintained | 1 Aug 2025 |
Financial journalist opinion
Based on 19 articles about ARGX published over the past 30 days
